A patient-specific neoantigen peptide vaccine designed to elicit anti-tumor immunity by promoting dendritic cell/MHC presentation of tumor-derived neoantigens, priming and expanding tumor-specific CD8+ cytotoxic and CD4+ helper T cells and generating immune memory.
Patient-specific tumor neoantigen peptides are taken up by dendritic cells and presented on MHC class I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells to mediate tumor cell killing and establish durable immune memory.
NO
INDIRECT
The vaccine primes neoantigen-specific CD8+ T cells that recognize tumor neoantigen peptides presented on MHC I (e.g., HLA-B) and kill those tumor cells via perforin/granzyme; HLA-B expression alone is not targeted.
A patient-specific neoantigen peptide vaccine designed to elicit anti-tumor immunity by promoting dendritic cell/MHC presentation of tumor-derived neoantigens, priming and expanding tumor-specific CD8+ cytotoxic and CD4+ helper T cells and generating immune memory.
Patient-specific tumor neoantigen peptides are taken up by dendritic cells and presented on MHC class I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells to mediate tumor cell killing and establish durable immune memory.
NO
INDIRECT
The vaccine primes neoantigen-specific CD8+ T cells that kill cells presenting the neoantigen peptide on MHC I via perforin/granzyme or Fas-FasL. HLA-C itself is not the target of killing.
A patient-specific neoantigen peptide vaccine designed to elicit anti-tumor immunity by promoting dendritic cell/MHC presentation of tumor-derived neoantigens, priming and expanding tumor-specific CD8+ cytotoxic and CD4+ helper T cells and generating immune memory.
Patient-specific tumor neoantigen peptides are taken up by dendritic cells and presented on MHC class I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells to mediate tumor cell killing and establish durable immune memory.
NO
INDIRECT
The vaccine uses HLA-DR on antigen-presenting cells to present peptides and prime neoantigen-specific T cells; the resulting CD8+ CTLs kill tumor cells presenting the neoantigen on MHC I via perforin/granzyme, not by targeting HLA-DR-expressing cells.
A patient-specific neoantigen peptide vaccine designed to elicit anti-tumor immunity by promoting dendritic cell/MHC presentation of tumor-derived neoantigens, priming and expanding tumor-specific CD8+ cytotoxic and CD4+ helper T cells and generating immune memory.
Patient-specific tumor neoantigen peptides are taken up by dendritic cells and presented on MHC class I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells to mediate tumor cell killing and establish durable immune memory.
NO
INDIRECT
The vaccine’s peptides are presented (including via HLA-DQ) to prime T cells; activated CD8+ T cells then kill tumor cells displaying neoantigens on MHC I via perforin/granzyme, not cells expressing HLA-DQ.
A patient-specific neoantigen peptide vaccine designed to elicit anti-tumor immunity by promoting dendritic cell/MHC presentation of tumor-derived neoantigens, priming and expanding tumor-specific CD8+ cytotoxic and CD4+ helper T cells and generating immune memory.
Patient-specific tumor neoantigen peptides are taken up by dendritic cells and presented on MHC class I and II, priming and expanding neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells to mediate tumor cell killing and establish durable immune memory.
NO
INDIRECT
The vaccine primes neoantigen-specific T cells; CTLs kill cells presenting the specific neoantigen peptide on MHC, not cells merely expressing HLA-DP (MHC II) itself.